Dr. Brahmer on Distinguishing Between Response and Growth

Video

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses how physicians distinguish between a response to an immunotherapy and cancer growth.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses how physicians distinguish between a response to an immunotherapy and cancer growth.

The main way this is distinguished is by looking at how the patient is doing, Brahmer says. If a patient is otherwise clinically well and their disease is getting slightly worse, a physician should allow for that patient to remain on immunotherapy for another cycle. If a patient’s disease continues to progress even if he/she is feeling well, Brahmer says, a physician should not keep their patient on the drug. If a patients is doing poorly and his/her cancer is progressing, it is definitely time that immunotherapy be discontinued, Brahmer says.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD